VistaGen Therapeutics's total assets for Q2 2025 were $102.50M, a decrease of -9.73% from the previous quarter. VTGN total liabilities were $9.52M for the fiscal quarter, a 8.89% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.